PhaseBio Pharmaceuticals, Inc. Positions for the Next Stage of Development by Bringing on Board Industry Veteran, Jonathan Mow as Chief Business Officer
12/4/2012 10:50:15 AM
More...
|
PhaseBio Pharmaceuticals, Inc. Initiates a Multicenter, Randomized Placebo and Active Comparator Controlled Phase 2b Trial to Evaluate Use of Glymera for the Treatment of Uncontrolled Type 2 Diabetes
8/21/2012 9:54:55 AM
More...
|
PhaseBio Pharmaceuticals, Inc. Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing for Advancement of Metabolic and Cardiovascular Product Portfolio
6/5/2012 7:34:43 AM
More...
|
PhaseBio Pharmaceuticals, Inc. Launches Clinical Program to Evaluate Novel VPAC2 Agonist for Cardiovascular Disease
2/22/2012 6:34:11 AM
More...
|
PhaseBio Pharmaceuticals, Inc. Announces Positive Clinical Results with its Once Weekly GLP-1 analogue, Glymera™ for the Treatment of Hyperglycemia in Patients with Type 2 Diabetes
11/15/2011 11:16:02 AM
More...
|
PhaseBio Pharmaceuticals, Inc. Announces the Appointment of Kathryn J. Gregory Vice President of Business Development
4/27/2011 8:31:32 AM
More...
|
PhaseBio Pharmaceuticals, Inc. Reaches Key Milestones and Receives $15 Million to Complete Series B Financing
12/2/2010 7:36:33 AM
More...
|
PhaseBio Pharmaceuticals, Inc. Launches Clinical Program to Test Lead Product for Sustained 24/7 Glycemic Control in Type 2 Diabetics
12/1/2010 9:54:17 AM
More...
|
PhaseBio Pharmaceuticals, Inc. Raises $25 Million in Series B Funding, Initiates Collaboration with OSI Pharmaceuticals, Inc. (OSIP)
1/8/2010 7:11:33 AM
More...
|
PhaseBio Pharmaceuticals, Inc. Raises $25 Million in Series B Funding, Initiates Collaboration with OSI Pharmaceuticals, Inc. (OSIP)
1/7/2010 1:19:26 PM
More...
|